260 related articles for article (PubMed ID: 28232751)
1. CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.
Funnell T; Tasaki S; Oloumi A; Araki S; Kong E; Yap D; Nakayama Y; Hughes CS; Cheng SG; Tozaki H; Iwatani M; Sasaki S; Ohashi T; Miyazaki T; Morishita N; Morishita D; Ogasawara-Shimizu M; Ohori M; Nakao S; Karashima M; Sano M; Murai A; Nomura T; Uchiyama N; Kawamoto T; Hara R; Nakanishi O; Shumansky K; Rosner J; Wan A; McKinney S; Morin GB; Nakanishi A; Shah S; Toyoshiba H; Aparicio S
Nat Commun; 2017 Feb; 8(1):7. PubMed ID: 28232751
[TBL] [Abstract][Full Text] [Related]
2. Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid.
Jiang K; Patel NA; Watson JE; Apostolatos H; Kleiman E; Hanson O; Hagiwara M; Cooper DR
Endocrinology; 2009 May; 150(5):2087-97. PubMed ID: 19116344
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.
Iwai K; Yaguchi M; Nishimura K; Yamamoto Y; Tamura T; Nakata D; Dairiki R; Kawakita Y; Mizojiri R; Ito Y; Asano M; Maezaki H; Nakayama Y; Kaishima M; Hayashi K; Teratani M; Miyakawa S; Iwatani M; Miyamoto M; Klein MG; Lane W; Snell G; Tjhen R; He X; Pulukuri S; Nomura T
EMBO Mol Med; 2018 Jun; 10(6):. PubMed ID: 29769258
[TBL] [Abstract][Full Text] [Related]
4. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells.
Eisenreich A; Bogdanov VY; Zakrzewicz A; Pries A; Antoniak S; Poller W; Schultheiss HP; Rauch U
Circ Res; 2009 Mar; 104(5):589-99. PubMed ID: 19168442
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing.
Araki S; Dairiki R; Nakayama Y; Murai A; Miyashita R; Iwatani M; Nomura T; Nakanishi O
PLoS One; 2015; 10(1):e0116929. PubMed ID: 25581376
[TBL] [Abstract][Full Text] [Related]
6. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models.
Tam BY; Chiu K; Chung H; Bossard C; Nguyen JD; Creger E; Eastman BW; Mak CC; Ibanez M; Ghias A; Cahiwat J; Do L; Cho S; Nguyen J; Deshmukh V; Stewart J; Chen CW; Barroga C; Dellamary L; Kc SK; Phalen TJ; Hood J; Cha S; Yazici Y
Cancer Lett; 2020 Mar; 473():186-197. PubMed ID: 31560935
[TBL] [Abstract][Full Text] [Related]
7. Regulation of influenza A virus mRNA splicing by CLK1.
Artarini A; Meyer M; Shin YJ; Huber K; Hilz N; Bracher F; Eros D; Orfi L; Keri G; Goedert S; Neuenschwander M; von Kries J; Domovich-Eisenberg Y; Dekel N; Szabadkai I; Lebendiker M; Horváth Z; Danieli T; Livnah O; Moncorgé O; Frise R; Barclay W; Meyer TF; Karlas A
Antiviral Res; 2019 Aug; 168():187-196. PubMed ID: 31176694
[TBL] [Abstract][Full Text] [Related]
8. Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors.
Murai A; Ebara S; Sasaki S; Ohashi T; Miyazaki T; Nomura T; Araki S
PLoS One; 2020; 15(10):e0240718. PubMed ID: 33064779
[TBL] [Abstract][Full Text] [Related]
9. Clk/STY (cdc2-like kinase 1) and Akt regulate alternative splicing and adipogenesis in 3T3-L1 pre-adipocytes.
Li P; Carter G; Romero J; Gower KM; Watson J; Patel NA; Cooper DR
PLoS One; 2013; 8(1):e53268. PubMed ID: 23308182
[TBL] [Abstract][Full Text] [Related]
10. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.
Fedorov O; Huber K; Eisenreich A; Filippakopoulos P; King O; Bullock AN; Szklarczyk D; Jensen LJ; Fabbro D; Trappe J; Rauch U; Bracher F; Knapp S
Chem Biol; 2011 Jan; 18(1):67-76. PubMed ID: 21276940
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells.
Bowler E; Porazinski S; Uzor S; Thibault P; Durand M; Lapointe E; Rouschop KMA; Hancock J; Wilson I; Ladomery M
BMC Cancer; 2018 Apr; 18(1):355. PubMed ID: 29606096
[TBL] [Abstract][Full Text] [Related]
12. Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A.
Yomoda J; Muraki M; Kataoka N; Hosoya T; Suzuki M; Hagiwara M; Kimura H
Genes Cells; 2008 Mar; 13(3):233-44. PubMed ID: 18298798
[TBL] [Abstract][Full Text] [Related]
13. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
[TBL] [Abstract][Full Text] [Related]
14. Manipulation of alternative splicing by a newly developed inhibitor of Clks.
Muraki M; Ohkawara B; Hosoya T; Onogi H; Koizumi J; Koizumi T; Sumi K; Yomoda J; Murray MV; Kimura H; Furuichi K; Shibuya H; Krainer AR; Suzuki M; Hagiwara M
J Biol Chem; 2004 Jun; 279(23):24246-54. PubMed ID: 15010457
[TBL] [Abstract][Full Text] [Related]
15. Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention.
Uzor S; Zorzou P; Bowler E; Porazinski S; Wilson I; Ladomery M
Gene; 2018 Sep; 670():46-54. PubMed ID: 29802995
[TBL] [Abstract][Full Text] [Related]
16. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
Debdab M; Carreaux F; Renault S; Soundararajan M; Fedorov O; Filippakopoulos P; Lozach O; Babault L; Tahtouh T; Baratte B; Ogawa Y; Hagiwara M; Eisenreich A; Rauch U; Knapp S; Meijer L; Bazureau JP
J Med Chem; 2011 Jun; 54(12):4172-86. PubMed ID: 21615147
[TBL] [Abstract][Full Text] [Related]
17. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.
Nowak DG; Woolard J; Amin EM; Konopatskaya O; Saleem MA; Churchill AJ; Ladomery MR; Harper SJ; Bates DO
J Cell Sci; 2008 Oct; 121(Pt 20):3487-95. PubMed ID: 18843117
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase clk/STY is differentially regulated during erythroleukemia cell differentiation: a bias toward the skipped splice variant characterizes postcommitment stages.
García-Sacristán A; Fernández-Nestosa MJ; Hernández P; Schvartzman JB; Krimer DB
Cell Res; 2005 Jul; 15(7):495-503. PubMed ID: 16045812
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells.
Gonçalves V; Henriques AF; Pereira JF; Neves Costa A; Moyer MP; Moita LF; Gama-Carvalho M; Matos P; Jordan P
RNA; 2014 Apr; 20(4):474-82. PubMed ID: 24550521
[TBL] [Abstract][Full Text] [Related]
20. A novel link of HLA locus to the regulation of immunity and infection: NFKBIL1 regulates alternative splicing of human immune-related genes and influenza virus M gene.
An J; Nakajima T; Shibata H; Arimura T; Yasunami M; Kimura A
J Autoimmun; 2013 Dec; 47():25-33. PubMed ID: 23953137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]